title: Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.
abstract: BACKGROUND
  Substantial weight gain is common with many atypical antipsychotics.
  
  
  OBJECTIVE
  To evaluate the extent, time course and predictors of weight gain and its effect on study retention among people with first-episode psychosis treated with olanzapine or haloperidol.
  
  
  METHODS
  Survival analysis assessed time to potentially clinically significant weight gain (> or =7%) and the effect of weight gain on study retention. Weight gain during the 2-year study was summarised using last-observation-carried-forward (LOCF), observed cases and study completion approaches.
  
  
  RESULTS
  After 2 years of treatment, LOCF mean weight gain was 10.2 kg (s.d.=10.1) for olanzapine (n=131) and 4.0 kg (s.d.=7.3) for haloperidol (n=132); observed cases mean weight gain was 15.4 kg (s.d.=10.0) for olanzapine and 7.5 kg (s.d.=9.2) for haloperidol. Change in body mass index was significantly predicted only by treatment group (P < 0.0001).
  
  
  CONCLUSIONS
  Olanzapine was associated with significantly greater weight gain than haloperidol, with both leading to greater weight gain than previously described.
authors.affiliation: Schizophrenia Programme,Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8. robert_zipursky@camh.net
authors.forename: Robert B
authors.initials: RB
authors.lastname: Zipursky
authors.forename: Hongbin
authors.initials: H
authors.lastname: Gu
authors.forename: Alan I
authors.initials: AI
authors.lastname: Green
authors.forename: Diana O
authors.initials: DO
authors.lastname: Perkins
authors.forename: Mauricio F
authors.initials: MF
authors.lastname: Tohen
authors.forename: Joseph P
authors.initials: JP
authors.lastname: McEvoy
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Strakowski
authors.forename: Tonmoy
authors.initials: T
authors.lastname: Sharma
authors.forename: René S
authors.initials: RS
authors.lastname: Kahn
authors.forename: Raquel E
authors.initials: RE
authors.lastname: Gur
authors.forename: Gary D
authors.initials: GD
authors.lastname: Tollefson
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Lieberman
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006220:Haloperidol / Q000009:adverse effects*; D006801:Humans; D008297:Male; D000077152:Olanzapine; D010352:Patient Dropouts; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors; D016896:Treatment Outcome; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D002784:Cholesterol; D006220:Haloperidol; D000077152:Olanzapine